RELMADA THERAPEUTICS ($RLMD) posted quarterly earnings results for Q1 2026 on Tuesday, May 12th. The company reported earnings of -$0.22 per share, missing estimates of -$0.20 by $0.02. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $RLMD stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
RELMADA THERAPEUTICS Insider Trading Activity
RELMADA THERAPEUTICS insiders have traded $RLMD stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $RLMD stock by insiders over the last 6 months:
- SERGIO TRAVERSA (Chief Executive Officer) purchased 27,500 shares for an estimated $113,300
- MAGED SHENOUDA (Chief Financial Officer) purchased 11,665 shares for an estimated $48,059
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
RELMADA THERAPEUTICS Hedge Fund Activity
We have seen 54 institutional investors add shares of RELMADA THERAPEUTICS stock to their portfolio, and 8 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JANUS HENDERSON GROUP PLC added 7,270,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $35,114,100
- MARSHALL WACE, LLP added 2,917,609 shares (+1072.4%) to their portfolio in Q4 2025, for an estimated $14,092,051
- ORBIMED ADVISORS LLC added 2,610,600 shares (+inf%) to their portfolio in Q4 2025, for an estimated $12,609,198
- AMERIPRISE FINANCIAL INC added 1,920,099 shares (+inf%) to their portfolio in Q4 2025, for an estimated $9,274,078
- MILLENNIUM MANAGEMENT LLC added 1,673,017 shares (+inf%) to their portfolio in Q4 2025, for an estimated $8,080,672
- BRAIDWELL LP added 1,582,257 shares (+inf%) to their portfolio in Q4 2025, for an estimated $7,642,301
- IKARIAN CAPITAL, LLC added 1,225,299 shares (+66.5%) to their portfolio in Q4 2025, for an estimated $5,918,194
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
RELMADA THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $RLMD in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Leerink Partners issued a "Outperform" rating on 01/23/2026
- Jefferies issued a "Buy" rating on 12/22/2025
- Mizuho issued a "Outperform" rating on 11/19/2025
To track analyst ratings and price targets for RELMADA THERAPEUTICS, check out Quiver Quantitative's $RLMD forecast page.
RELMADA THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $RLMD recently. We have seen 5 analysts offer price targets for $RLMD in the last 6 months, with a median target of $12.0.
Here are some recent targets:
- Kelsey Goodwin from Piper Sandler set a target price of $12.0 on 03/24/2026
- Uy Ear from Mizuho set a target price of $19.0 on 03/20/2026
- Christopher Liu from LUCID CAPITAL MARKETS set a target price of $14.0 on 03/02/2026
- Andrew Berens from Leerink Partners set a target price of $8.0 on 01/23/2026
- Farzin Haque from Jefferies set a target price of $9.0 on 12/22/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
